467 related articles for article (PubMed ID: 24974063)
1. Macrophage activation syndrome and cytokine-directed therapies.
Schulert GS; Grom AA
Best Pract Res Clin Rheumatol; 2014 Apr; 28(2):277-92. PubMed ID: 24974063
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.
Schulert GS; Grom AA
Annu Rev Med; 2015; 66():145-59. PubMed ID: 25386930
[TBL] [Abstract][Full Text] [Related]
3. Macrophage activation syndrome in the era of biologic therapy.
Grom AA; Horne A; De Benedetti F
Nat Rev Rheumatol; 2016 May; 12(5):259-68. PubMed ID: 27009539
[TBL] [Abstract][Full Text] [Related]
4. Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome.
Inoue N; Schulert GS
Arthritis Res Ther; 2023 Mar; 25(1):48. PubMed ID: 36964620
[TBL] [Abstract][Full Text] [Related]
5. Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment.
Yasin S; Schulert GS
Curr Opin Rheumatol; 2018 Sep; 30(5):514-520. PubMed ID: 29870499
[TBL] [Abstract][Full Text] [Related]
6. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.
Put K; Avau A; Brisse E; Mitera T; Put S; Proost P; Bader-Meunier B; Westhovens R; Van den Eynde BJ; Orabona C; Fallarino F; De Somer L; Tousseyn T; Quartier P; Wouters C; Matthys P
Rheumatology (Oxford); 2015 Aug; 54(8):1507-17. PubMed ID: 25767156
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of Interleukin-18 as a Diagnostic Biomarker to Differentiate Adult-Onset Still's Disease With/Without Macrophage Activation Syndrome From Other Secondary Hemophagocytic Lymphohistiocytosis in Adults.
Shiga T; Nozaki Y; Tomita D; Kishimoto K; Hirooka Y; Kinoshita K; Funauchi M; Matsumura I
Front Immunol; 2021; 12():750114. PubMed ID: 34691064
[TBL] [Abstract][Full Text] [Related]
8. Natural Killer Cells in Systemic Autoinflammatory Diseases: A Focus on Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome.
Vandenhaute J; Wouters CH; Matthys P
Front Immunol; 2019; 10():3089. PubMed ID: 32010140
[TBL] [Abstract][Full Text] [Related]
9. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Bracaglia C; de Graaf K; Pires Marafon D; Guilhot F; Ferlin W; Prencipe G; Caiello I; Davì S; Schulert G; Ravelli A; Grom AA; de Min C; De Benedetti F
Ann Rheum Dis; 2017 Jan; 76(1):166-172. PubMed ID: 27296321
[TBL] [Abstract][Full Text] [Related]
10. The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome - a systematic review.
Krei JM; Møller HJ; Larsen JB
Clin Exp Immunol; 2021 Feb; 203(2):174-182. PubMed ID: 33128796
[TBL] [Abstract][Full Text] [Related]
11. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis.
Lehmberg K; Pink I; Eulenburg C; Beutel K; Maul-Pavicic A; Janka G
J Pediatr; 2013 Jun; 162(6):1245-51. PubMed ID: 23333131
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of macrophage activation syndrome and treatment progression.
Dong Y; Wang T; Wu H
Front Immunol; 2024; 15():1389710. PubMed ID: 38736876
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Moderately Dosed Etoposide in Macrophage Activation Syndrome-Hemophagocytic Lymphohistiocytosis.
Horne A; von Bahr Greenwood T; Chiang SCC; Meeths M; Björklund C; Ekelund M; Erensjö P; Berg S; Hagelberg S; Bryceson YT; Andersson U; Henter JI
J Rheumatol; 2021 Oct; 48(10):1596-1602. PubMed ID: 33589555
[TBL] [Abstract][Full Text] [Related]
14. The Immunology of Macrophage Activation Syndrome.
Crayne CB; Albeituni S; Nichols KE; Cron RQ
Front Immunol; 2019; 10():119. PubMed ID: 30774631
[TBL] [Abstract][Full Text] [Related]
15. Understanding of cytokines and targeted therapy in macrophage activation syndrome.
Tang S; Li S; Zheng S; Ding Y; Zhu D; Sun C; Hu Y; Qiao J; Fang H
Semin Arthritis Rheum; 2021 Feb; 51(1):198-210. PubMed ID: 33385860
[TBL] [Abstract][Full Text] [Related]
16. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.
Ravelli A; Grom AA; Behrens EM; Cron RQ
Genes Immun; 2012 Jun; 13(4):289-98. PubMed ID: 22418018
[TBL] [Abstract][Full Text] [Related]
17. Convergent pathways of the hyperferritinemic syndromes.
Schulert GS; Canna SW
Int Immunol; 2018 Apr; 30(5):195-203. PubMed ID: 29420734
[TBL] [Abstract][Full Text] [Related]
18. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
Put K; Brisse E; Avau A; Imbrechts M; Mitera T; Janssens R; Proost P; Fallarino F; Wouters CH; Matthys P
PLoS One; 2016; 11(2):e0150075. PubMed ID: 26914138
[TBL] [Abstract][Full Text] [Related]
19. An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
Arduini A; Marasco E; Marucci G; Pardeo M; Insalaco A; Caiello I; Moneta GM; Prencipe G; De Benedetti F; Bracaglia C
Pediatr Rheumatol Online J; 2019 May; 17(1):25. PubMed ID: 31118063
[TBL] [Abstract][Full Text] [Related]
20. Cloak and dagger: the case for adult onset still disease and hemophagocytic lymphohistiocytosis.
Félix FH; Leal LK; Fontenele JB
Rheumatol Int; 2009 Jun; 29(8):973-4. PubMed ID: 19115058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
